CCA
ALLO icon

Cygnus Capital Advisors’s Allogene Therapeutics ALLO Stock Holding History

Cygnus Capital Advisors’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$8 Hold
3,234
– – 0.01% 97
2025
Q4 		$4 Buy
+3,234
New +$4.27K ﹤0.01% 145

Other funds holding ALLO

P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Cygnus Capital Advisors's ALLO Position: Q1 2026 in Review

Cygnus Capital Advisors held its Allogene Therapeutics (ALLO) position steady in Q1 2026 at 3,234 shares worth $8. The position accounts for 0.01% of the portfolio, ranked #97.

Cygnus Capital Advisors first reported a position in ALLO in Q4 2025 and has held it in 2 quarters since. 209 funds tracked by Wall St. Rank hold ALLO as of Q1 2026.

  • Cygnus Capital Advisors held 3,234 shares of Allogene Therapeutics worth $8 as of Q1 2026.
  • Cygnus Capital Advisors left its Allogene Therapeutics share count unchanged in Q1 2026.
  • Allogene Therapeutics made up 0.01% of Cygnus Capital Advisors's portfolio in Q1 2026, its #97 holding.
  • Cygnus Capital Advisors first reported a position in Allogene Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • 209 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q1 2026.

Based on Cygnus Capital Advisors's 13F filing for Q1 2026, filed 13 May 2026.